WO1998027108A3 - Nouveaux composes amide - Google Patents

Nouveaux composes amide Download PDF

Info

Publication number
WO1998027108A3
WO1998027108A3 PCT/JP1997/004243 JP9704243W WO9827108A3 WO 1998027108 A3 WO1998027108 A3 WO 1998027108A3 JP 9704243 W JP9704243 W JP 9704243W WO 9827108 A3 WO9827108 A3 WO 9827108A3
Authority
WO
WIPO (PCT)
Prior art keywords
nitric oxide
pharmaceutically acceptable
acceptable salts
compound
cerebral
Prior art date
Application number
PCT/JP1997/004243
Other languages
English (en)
Other versions
WO1998027108A2 (fr
Inventor
Takumi Di Yatabe
Yoshikuni Itoh
Takayuki Inoue
Hitoshi Hamashima
Ichiro Shima
Kazuhiko Ohne
Kousei Yoshihara
Teruo Oku
Original Assignee
Fujisawa Pharmaceutical Co
Yatabe Yoshiko & Hf
Yoshikuni Itoh
Takayuki Inoue
Hitoshi Hamashima
Ichiro Shima
Kazuhiko Ohne
Kousei Yoshihara
Teruo Oku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO4219A external-priority patent/AUPO421996A0/en
Priority claimed from AUPO5929A external-priority patent/AUPO592997A0/en
Priority claimed from AUPO9030A external-priority patent/AUPO903097A0/en
Application filed by Fujisawa Pharmaceutical Co, Yatabe Yoshiko & Hf, Yoshikuni Itoh, Takayuki Inoue, Hitoshi Hamashima, Ichiro Shima, Kazuhiko Ohne, Kousei Yoshihara, Teruo Oku filed Critical Fujisawa Pharmaceutical Co
Priority to JP52752898A priority Critical patent/JP2001505585A/ja
Priority to AU49680/97A priority patent/AU4968097A/en
Priority to EP97912529A priority patent/EP0946587A2/fr
Publication of WO1998027108A2 publication Critical patent/WO1998027108A2/fr
Publication of WO1998027108A3 publication Critical patent/WO1998027108A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composé de formule (I) et sels pharmaceutiquement acceptables de ce composé. Dans ladite formule, chaque symbole est tel que défini dans la description. Le composé et les sels pharmaceutiquement acceptables considérés ont un fort effet inhibiteur sur la production d'oxyde nitrique (NO) et sont utiles pour prévenir et/ou traiter les maladies à médiation NO, chez l'homme et l'animal, à savoir par exemple: syndrome de détresse respiratoire aiguë de l'adulte, ischémie cardiovasculaire, myocardite, insuffisance cardiaque, synovite, choc, diabète, néphropathie diabétique, rétinopathie diabétique, neuropathie diabétique, glomérulonéphrite, ulcère gastroduodénal, maladie intestinale inflammatoire, infarctus cérébral, ischémie cérébrale, hémorragie cérébrale, migraine, polyarthrite rhumatoïde, goutte, névrite, algies postzostériennes, arthrose, ostéoporose, lupus érythémateux aigu disséminé, rejet d'une transplantation d'organe, asthme, métastase, maladie d'Alzheimer, arthrite, troubles du système nerveux central, dermatite, hépatite, cirrhose du foie, sclérose en plaques, pancréatite, athérosclérose et autres.
PCT/JP1997/004243 1996-12-16 1997-11-20 Nouveaux composes amide WO1998027108A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP52752898A JP2001505585A (ja) 1996-12-16 1997-11-20 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途
AU49680/97A AU4968097A (en) 1996-12-16 1997-11-20 New amide compounds
EP97912529A EP0946587A2 (fr) 1996-12-16 1997-11-20 Nouveaux composes amide

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AUPO4219A AUPO421996A0 (en) 1996-12-16 1996-12-16 New amide compounds
AUPO4219 1996-12-16
AUPO5929A AUPO592997A0 (en) 1997-04-01 1997-04-01 New amide compounds
AUPO5929 1997-04-01
AUPO9030 1997-09-09
AUPO9030A AUPO903097A0 (en) 1997-09-09 1997-09-09 New amide compounds

Publications (2)

Publication Number Publication Date
WO1998027108A2 WO1998027108A2 (fr) 1998-06-25
WO1998027108A3 true WO1998027108A3 (fr) 1998-07-30

Family

ID=27157969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1997/004243 WO1998027108A2 (fr) 1996-12-16 1997-11-20 Nouveaux composes amide

Country Status (3)

Country Link
EP (1) EP0946587A2 (fr)
JP (1) JP2001505585A (fr)
WO (1) WO1998027108A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101706545B1 (ko) 2010-03-04 2017-02-14 이에이 파마 가부시키가이샤 알킬아민 유도체
US11566026B2 (en) 2016-12-22 2023-01-31 Incyte Corporation Heterocyclic compounds as immunomodulators

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030709A1 (fr) * 1997-12-17 1999-06-24 Merck & Co., Inc. Antagonistes du recepteur de l'integrine
DE19816880A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
WO1999051215A2 (fr) * 1998-04-06 1999-10-14 Fujisawa Pharmaceutical Co., Ltd. Nouvelle utilisation
JP2002511889A (ja) * 1998-05-04 2002-04-16 藤沢薬品工業株式会社 一酸化窒素産生阻害剤としての複素環カルボキサミド誘導体
US6852725B1 (en) * 1998-06-12 2005-02-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S. A. S. Imidazolyl derivatives
ATE494388T1 (de) 1999-01-13 2011-01-15 Univ New York State Res Found Neues verfahren zum erschaffen von proteinkinase- inhibitoren
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
AUPQ142599A0 (en) * 1999-07-05 1999-07-29 Fujisawa Pharmaceutical Co., Ltd. New amide compounds
FR2812546B1 (fr) * 2000-08-01 2008-11-21 Sod Conseils Rech Applic Derives d'heterocycles a 5 chainons, leur preparation et leur application a titre de medicaments
TWI292316B (en) * 1999-10-11 2008-01-11 Sod Conseils Rech Applic Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof
KR100822085B1 (ko) * 1999-10-11 2008-04-15 소시에떼 드 꽁세이으 드 르세르세 에 따블리까시옹 시앙띠피끄 (에스.세.에르.아.에스.) 5-원 헤테로사이클 유도체, 이의 제조 방법 및의약으로서의 이의 용도
US6525051B2 (en) * 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
AU7909801A (en) 2000-08-01 2002-02-13 Sod Conseils Rech Applic Imidazolyl derivatives
DE60128731T2 (de) * 2000-10-30 2008-02-07 Janssen Pharmaceutica N.V. Tripeptidylpeptidase-hemmer
WO2002069965A1 (fr) * 2001-03-05 2002-09-12 Transtech Pharma, Inc. Agents thérapeutiques à base de dérivés benzimidazole
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
KR20040031782A (ko) 2001-07-27 2004-04-13 쿠리스 인코퍼레이션 헤지호그 신호전달 경로의 조절물질, 이를 함유하는조성물 및 이의 용도
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
MXPA04003758A (es) * 2001-10-22 2005-06-20 Univ New York State Res Found Inhibidores de proteina - cinasas y proteina-fosfatasas, metodos para disenarlos y metodos para usarlos.
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
CA2479928A1 (fr) * 2002-03-28 2003-10-09 Neurogen Corporation Biarylamides substitues en tant que modulateurs du recepteur c5a
US6858637B2 (en) 2002-03-28 2005-02-22 Neurogen Corporation Substituted biaryl amides as C5a receptor modulators
EP1546110A4 (fr) * 2002-07-30 2008-03-26 Univ Virginia Composes actifs dans la signalisation de sphingosine 1-phosphate
AU2003257329C1 (en) 2002-08-19 2010-07-22 Lorus Therapeutics Inc. 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
DE10332560B4 (de) * 2003-07-11 2010-07-08 Chiracon Gmbh Verfahren zur Herstellung von ß- Heteroaryl-2-alanin-Verbindungen über 2-Amino-2-(heteroarylmethyl)-carbonsäure-Verbindungen
WO2005047266A1 (fr) 2003-11-14 2005-05-26 Lorus Therapeutics Inc. Imidazoles d'aryle et leur utilisation comme agents anticancereux
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7576221B2 (en) 2004-06-18 2009-08-18 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole derivatives
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
WO2006028970A1 (fr) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derives d'inhibiteurs de thiazole et de thiadiazole de tyrosine phosphatases
JP2008521853A (ja) * 2004-12-02 2008-06-26 プロビオドルグ エージー 神経疾患治療用の新規化合物
JP2008007405A (ja) * 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
US7863294B2 (en) * 2004-12-10 2011-01-04 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Heterocycle derivatives as histone deacetylase (HDAC) inhibitors
CN101248072B (zh) 2005-05-25 2013-01-23 劳洛斯治疗公司 2-吲哚基咪唑并[4,5-d]菲咯啉衍生物及其在癌症治疗中的用途
MY147188A (en) 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
GB0522130D0 (en) 2005-10-31 2005-12-07 Angeletti P Ist Richerche Bio Therapeutic compounds
US7626039B2 (en) 2005-12-14 2009-12-01 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors
EP2044061A2 (fr) * 2006-07-20 2009-04-08 Mehmet Kahraman Inhibiteurs de la rho kinase à base de benzothiophène
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101622247A (zh) 2007-01-05 2010-01-06 诺瓦提斯公司 作为驱动蛋白纺锤体蛋白抑制剂的咪唑衍生物
WO2009018657A1 (fr) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Inhibiteurs de polymerase virale
US7990335B2 (en) 2007-12-05 2011-08-02 Antennas Direct, Inc. Antenna assemblies with antenna elements and reflectors
EP2234977A4 (fr) 2007-12-19 2011-04-13 Boehringer Ingelheim Int Inhibiteurs de polymérase virale
KR20100093129A (ko) 2007-12-20 2010-08-24 노파르티스 아게 Ｐｉ ３ 키나제 억제제로서 사용되는 티아졸 유도체
EP2242751B1 (fr) * 2008-02-12 2015-07-15 Bristol-Myers Squibb Company Dérivés hétérocycliques inhibiteurs du virus de l'hépatite c
USD883265S1 (en) 2008-02-29 2020-05-05 Antennas Direct, Inc. Antenna
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
WO2011041198A1 (fr) 2009-09-30 2011-04-07 Transtech Pharma, Inc. Dérivés d'imidazole substitués pour traiter la maladie d'alzheimer
RU2012129882A (ru) * 2009-12-16 2014-01-27 Нейропор Терапиз, Инк. Соединение
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基－雜芳基衍生物及其使用方法
KR20160042811A (ko) 2013-03-20 2016-04-20 압토스 바이오사이언시스 인코포레이티드 2-치환 이미다조[4,5-d]페난쓰롤린 유도체 및 암 치료에 있어서의 이의 용도
AR097279A1 (es) * 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
WO2015051304A1 (fr) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions, biomarqueurs et leur utilisation dans le traitement du cancer
WO2015142001A2 (fr) * 2014-03-21 2015-09-24 충남대학교산학협력단 Composé doté d'une action cardiotonique et composition pharmaceutique permettant de prévenir ou de traiter l'insuffisance cardiaque et contenant ledit composé
ES2832148T3 (es) * 2014-08-13 2021-06-09 Nippon Soda Co Compuesto diarilimidazol y agente de control de plagas
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MA44474A (fr) 2015-10-23 2019-01-30 Vifor Int Ag Nouveaux inhibiteurs de la ferroportine
AU2016358100B2 (en) 2015-11-19 2021-05-27 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE054503T2 (hu) 2015-12-16 2021-09-28 Nippon Soda Co Arilazol vegyület és kártevõ elleni szer
KR20180100585A (ko) 2015-12-22 2018-09-11 인사이트 코포레이션 면역조절제로서의 헤테로사이클릭 화합물
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
EP3464279B1 (fr) 2016-05-26 2021-11-24 Incyte Corporation Composés hétérocycliques comme immunomodulateurs
LT3472167T (lt) 2016-06-20 2022-11-10 Incyte Corporation Heterocikliniai junginiai kaip imunomoduliatoriai
US10899748B2 (en) * 2016-06-21 2021-01-26 Shifa Biomedical Corporation Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018044783A1 (fr) 2016-08-29 2018-03-08 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
WO2018119266A1 (fr) 2016-12-22 2018-06-28 Incyte Corporation Dérivés de benzooxazole en tant qu'mmunomodulateurs
WO2018119221A1 (fr) 2016-12-22 2018-06-28 Incyte Corporation Dérivés pyridine utilisés en tant qu'immunomodulateurs
HUE060233T2 (hu) 2016-12-22 2023-02-28 Incyte Corp Tetrahidro imidazo[4,5-c]piridin-származékok mint a PD-L1 internalizációját indukáló szerek
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
CN111417395A (zh) 2017-10-30 2020-07-14 艾普托斯生物科学公司 用于治疗癌症的芳基咪唑
MD3774791T2 (ro) 2018-03-30 2023-06-30 Incyte Corp Compuși heterociclici ca imunomodulatori
SI3790877T1 (sl) 2018-05-11 2023-06-30 Incyte Corporation Tetrahidro-imidazo(4,5-c)piridinski derivati kot imunomodulatorji pd-l1
EP4010342A1 (fr) 2019-08-09 2022-06-15 Incyte Corporation Sels d'un inhibiteur de pd-1/pd-l1
TW202126652A (zh) 2019-09-30 2021-07-16 美商英塞特公司 作為免疫調節劑之吡啶并［３，２—ｄ］嘧啶化合物
EP4058461A1 (fr) 2019-11-11 2022-09-21 Incyte Corporation Formes salines et cristallines d'un inhibiteur de pd-1/pd-l1
CN113683598B (zh) * 2020-05-18 2022-10-14 成都先导药物开发股份有限公司 一种免疫调节剂
JP2023548859A (ja) 2020-11-06 2023-11-21 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤ならびにその塩及び結晶形態を作製するためのプロセス
WO2022099075A1 (fr) 2020-11-06 2022-05-12 Incyte Corporation Forme cristalline d'un inhibiteur pd-1/pd-l1
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0491525A1 (fr) * 1990-12-18 1992-06-24 Eli Lilly And Company Benzamides et sulfonamides comme agents hypoglycémiques
WO1996016981A2 (fr) * 1994-12-02 1996-06-06 Fujisawa Pharmaceutical Co., Ltd. Composes peptidiques pour la prevention et/ou le traitement de maladies induites par no

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0491525A1 (fr) * 1990-12-18 1992-06-24 Eli Lilly And Company Benzamides et sulfonamides comme agents hypoglycémiques
WO1996016981A2 (fr) * 1994-12-02 1996-06-06 Fujisawa Pharmaceutical Co., Ltd. Composes peptidiques pour la prevention et/ou le traitement de maladies induites par no

Non-Patent Citations (32)

* Cited by examiner, † Cited by third party
Title
AM. CHEM. J., vol. 47, 1912, pages 234 - 236 *
ARCH. PHARM., vol. 312, 1979, pages 198 - 205 *
CHEM. HETEROCYCL. COMPD. (ENGL. TRANSL.), vol. 6, 1970, pages 486 - 488 *
CHEM. PHARM. BULL., vol. 17, 1969, pages 2381 *
CHEMICAL ABSTRACTS, vol. 81, no. 7, 19 August 1974, Columbus, Ohio, US; abstract no. 37511r, HEINISCH G ET AL: "2-Dialkylaminoacylaminoimidazoles as potential local anesthetics." page 385; column 1; XP002057314 *
CROSS D F W ET AL: "Peptides. Part XIV. Thiazoleamino-acids, Degradation Products of Thiostrepton.", JOURNAL OF THE CHEMICAL SOCIETY., April 1963 (1963-04-01), LETCHWORTH GB, pages 2143 - 2150, XP002057308 *
DATABASE CROSSFIRE Beilstein Informationssysteme GmbH; XP002057315 *
DATABASE CROSSFIRE Beilstein Informationssysteme GmbH; XP002057316 *
DATABASE CROSSFIRE Beilstein Informationssysteme GmbH; XP002057317 *
DATABASE CROSSFIRE Beilstein Informationssysteme GmbH; XP002057318 *
DATABASE CROSSFIRE Beilstein Informationssysteme GmbH; XP002057319 *
DATABASE CROSSFIRE Beilstein Informationssysteme GmbH; XP002057320 *
DATABASE CROSSFIRE Beilstein Informationssysteme GmbH; XP002057321 *
DATABASE CROSSFIRE Beilstein Informationssysteme GmbH; XP002057322 *
DATABASE CROSSFIRE Beilstein Informationssysteme GmbH; XP002057323 *
GERBERT U ET AL: "Model reactions for enzymic catalysis. IV. Structure-activity relationship of new transaminators with imidazole, thiazole, and benzimidazole skeletons", JUSTUS LIEBIGS ANN. CHEM., no. 4, 1974, pages 644 - 654, XP002057306 *
GORDON T D ET AL: "Synthetic Approaches to the 'Azole' Peptide Mimetics", TETRAHEDRON LETTERS., vol. 34, no. 12, 19 March 1993 (1993-03-19), OXFORD GB, pages 1901 - 1904, XP002038851 *
HAMADA Y ET AL: "New methods and reagents in organic synthesis. 67. A general synthesis of derivatives of optically pure 2-(1-aminoalkyl)thiazole-4 -carboxylic acids", J. ORG. CHEM., vol. 52, no. 7, 3 April 1987 (1987-04-03), pages 1252 - 1255, XP002057304 *
LI G ET AL: "Synthesis of a Directly Connected Thiazole-Oxazole Ring System Present in Microcin B17", J. ORG. CHEM., vol. 61, no. 2, 26 January 1996 (1996-01-26), pages 778 - 780, XP002057303 *
LIEBSCHER J ET AL: "Formylation Products of Thioamides; Part 12. Synthesis of Thiazoles by the Reaction of S-Alkylated Thioamides or Thioureas with Acid Derivatives", SYNTHESIS., no. 4, April 1985 (1985-04-01), STUTTGART DE, pages 414 - 417, XP002057313 *
MOFFETT R B ET AL: "Antiulcer Agents. p-Aminobenzamido Aromatic Compounds", JOURNAL OF MEDICINAL CHEMISTRY., vol. 14, no. 10, October 1971 (1971-10-01), WASHINGTON US, pages 963 - 968, XP002057311 *
NAIR V ET AL: "Regioselective [4+2] and [2+2] Cycloadditions of 1-Azirines to Heterocumulenes. Formation and Rearrangements of the Cycloadducts", JOURNAL OF ORGANIC CHEMISTRY., vol. 39, no. 25, 13 December 1974 (1974-12-13), EASTON US, pages 3763 - 3767, XP002057312 *
PETTIT G R ET AL: "Antineoplastic agents. 109. Structural biochemistry. 24. Synthesis of the cyclo-[(gly)Thz-(R)- and (S)-(gln)Thz-L-Val-L-Leu-L -Pro] isomers of dolastatin 3", J. ORG. CHEM., vol. 50, no. 15, 26 July 1985 (1985-07-26), pages 2654 - 2659, XP002057305 *
PYL T ET AL: "Zur Darstellung von 7-Benzoylamino-pyrrolo[2.1-b]thiazolen", JUSTUS LIEBIGS ANNALEN DER CHEMIE., vol. 676, 1964, WEINHEIM DE, pages 141 - 150, XP002057309 *
PYL T ET AL: "Zur Kenntnis der Imidazo[5.1-b]thiazole", JUSTUS LIEBIGS ANNALEN DER CHEMIE., vol. 679, 1964, WEINHEIM DE, pages 144 - 150, XP002057310 *
REV. ROUM. CHIM., vol. 10, 1965, pages 617 - 620 *
SCI. PHARM., vol. 42, no. 1, 1974, pages 19 - 33 *
SETO Y ET AL: "Unusual amino acids and their peptides. V. Synthesis and the absolute configuration of.beta.-(2-thiazolyl)-.beta.-alanine present in bottromycin", BULL. CHEM. SOC. JAP., vol. 47, no. 1, January 1974 (1974-01-01), pages 151 - 155, XP002057307 *
STUD. UNIV. BABES-BOLYAI CHEM., vol. 1, 1960, pages 155 *
SYNTH. COMMUN., vol. 18, no. 7, 1988, pages 651 - 658 *
TETRAHEDRON., vol. 30, 1974, OXFORD GB, pages 3859 - 3864 *
UKR. KHIM. ZH. (RUSS. ED.), vol. 21, 1955, pages 726 - 729 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101706545B1 (ko) 2010-03-04 2017-02-14 이에이 파마 가부시키가이샤 알킬아민 유도체
US11566026B2 (en) 2016-12-22 2023-01-31 Incyte Corporation Heterocyclic compounds as immunomodulators

Also Published As

Publication number Publication date
JP2001505585A (ja) 2001-04-24
WO1998027108A2 (fr) 1998-06-25
EP0946587A2 (fr) 1999-10-06

Similar Documents

Publication Publication Date Title
WO1998027108A3 (fr) Nouveaux composes amide
AU2004314287B2 (en) Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme
EP1541563A4 (fr) Antagoniste du ccr4 et utilisation medicinale correspondante
EP1454898A4 (fr) Nouveau derive de phenylalanine
US10604494B2 (en) Acylated N-(1 ,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)- and N-(triazol-5-yl)-aryl carboxamides, and use thereof as herbicides
BR0214345A (pt) Compostos derivados de piperidin-2-ona e composições farmacêuticas contendo estes compostos como ingrediente ativo
AR032318A1 (es) Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
WO2001014328A3 (fr) Urees substituees inhibiteurs d'adhesion cellulaire
WO2002069905A3 (fr) Co-administration de l'agoniste du recepteur de la melanocortine et inhibiteur de phosphodiesterase pour le traitement de troubles associes a l'amp cyclique
WO2006094187A3 (fr) Composes de phthalazine, aza- et diaza-phthalazine et procedes d'utilisation de ceux-ci
NO20021691L (no) Benzodiazepinderivater
WO2002070509A3 (fr) Antagonistes de la fonction mcp-1 et procede d'utilisation de ceux-ci
NZ532018A (en) Pyrrolidinone derivatives
DE60138658D1 (de) Carbaminsäurederivate enthaltend eine Amidgruppe zur Behandlung von Malaria
GB8830312D0 (en) Heterocyclic compounds
GEP20084526B (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders, process for their preparation and pharmaceutical compositions containing them
WO2007149395A3 (fr) Azoles dotés d'une activité inhibitrice enzymatique utilisant l'atp, compositions, et leurs utilisations
EP2928887B1 (fr) Amides d'acide n-(oxazol-2-yl)-aryle carbonique et leur utilisation comme herbicides
EP3317272B1 (fr) Dérivés de n-(1,3,4-oxadiazol-2-yl)aryl-carboxamide à action herbicide
SV1999000120A (es) 1-aril-3-arilmetil-1,8-naftiridin-4 (1h)-onas ref. pc10020/82739/bb
IL186777A0 (en) (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor
WO2008064342A3 (fr) Inhibiteurs de la pde10 et compositions et procédés apparentés
JP2007514638A5 (fr)
CN110357789A (zh) 作为dhodh抑制剂的n-取代丙烯酰胺衍生物及其制备和用途
WO2009147476A1 (fr) Nouveaux inhibiteurs de phosphodiestérases, compositions pharmaceutiques les contenant et leurs procédés de préparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN HU IL JP KR MX US AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN HU IL JP KR MX US AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 527528

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09319914

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1997912529

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997912529

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997912529

Country of ref document: EP